GAURI R VARADHACHARY to Neoplasms
This is a "connection" page, showing publications GAURI R VARADHACHARY has written about Neoplasms.
Connection Strength
0.151
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.029
-
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
Score: 0.027
-
Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. Radiology. 2017 05; 283(2):314-340.
Score: 0.024
-
Cost-effectiveness of gene-expression profiling for tumor-site origin. Value Health. 2013 Jan-Feb; 16(1):46-56.
Score: 0.018
-
Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival. Oncotarget. 2012 Jun; 3(6):620-8.
Score: 0.017
-
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct; 26(8):794-9.
Score: 0.013
-
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. 2008 Oct; 26(5):445-54.
Score: 0.013
-
Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs. 2006 May; 24(3):233-40.
Score: 0.011